ISPOR - PAR2- EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED CARE MEDICAID POPULATION

Full Text

PAR2- EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED CARE MEDICAID POPULATION

Abstract

Authors

DM Hartung DR Touchette K Ketchum DG Haxby

Back to Volume 6, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now